- DNA testing startup to lay off 40% of employees - Layoffs could affect 200+ employees at 23andMe - The startup is trying to stabilize a loss-making business - Also, 23andMe will close its drug development business - It was already testing two drugs on humans - 23andMe will try to sell promising drugs - Previously, drug development was its key bet - 23andMe still wants to license its data - It's about genetic data for pharmaceutical companies. - The startup is still trying to find additional partners - No new partners have emerged in the year since the GSK deal - The startup has had 5 rounds of layoffs since 2023 - New restructuring will save it up to $35 mln/year - 23andMe's core consumer business is unprofitable